PT-141 (Bremelanotide) · Research brief

PT-141 Safety Profile — Research & Clinical Data

Real Peptides Research TeamEditorial

Updated March 27, 202612 min read

60 WORDS

Short answer

The PT-141 safety profile looks remarkably clean compared to most pharmaceutical interventions targeting sexual dysfunction. Primarily because this melanocortin receptor agonist bypasses hepatic metabolism entirely. Research published in peer-reviewed journals shows that bremelanotide (PT-141's pharmaceutical designation) produces no clinically significant liver enzyme elevations, no QTc prolongation on electrocardiograms, and no drug-drug interactions with common medications metabolized through cytochrome P450 pathways.…

Key takeaways

PT-141 demonstrates favorable tolerability in Phase III trials with nausea (40%), flushing (20%), and headache (11%) representing the most common transient adverse events that resolve without intervention in over 90% of cases.
Cardiovascular safety data shows mean systolic blood pressure increases of only 3–5 mmHg at 90 minutes post-injection, returning to baseline within four hours. Uncontrolled hypertension above 160/100 mmHg remains the sole absolute contraindication.
PT-141 bypasses hepatic metabolism entirely through renal clearance, eliminating cytochrome P450 drug interactions and hepatotoxicity concerns that complicate most pharmaceutical interventions.
Peptide purity above 98% is critical for safety. Deletion sequences and truncation products from inadequate synthesis create unpredictable receptor binding profiles not captured in clinical trial data.
Discontinuation rates in clinical trials (3.7%) remain comparable to PDE5 inhibitors and lower than testosterone replacement therapy, with no serious adverse events causally linked to bremelanotide across 2,514 participants over 24 weeks.

What is the PT-141 safety profile based on clinical trial data?

The PT-141 safety profile demonstrates favorable tolerability across Phase II and Phase III randomized controlled trials, with nausea (40%), flushing (20%), and headache (11%) representing the most frequently reported adverse events. All transient and dose-dependent. Serious adverse events occurred in fewer than 2% of participants and showed no causal relationship to the peptide. Cardiovascular safety assessments revealed mean systolic blood pressure increases of 3–5 mmHg during the first 90 minutes post-injection, returning to baseline within four hours.

The direct answer most safety summaries skip: PT-141's mechanism of action through melanocortin-4 receptors in the hypothalamus means it works centrally rather than peripherally, creating a fundamentally different risk-benefit calculation than PDE5 inhibitors or vascular dilators. This article covers the specific adverse event rates from named clinical trials, the cardiovascular monitoring parameters that matter, contraindication profiles based on mechanism rather than marketing disclaimers, and what peptide purity actually means for safety when sourcing research-grade compounds.

Clinical Trial Safety Data and Adverse Event Profiles

The most comprehensive PT-141 safety profile data comes from the RECONNECT trials. Two Phase III, randomized, double-blind, placebo-controlled studies examining bremelanotide 1.75mg subcutaneous injection in premenopausal women with hypoactive sexual desire disorder. Trial 01 enrolled 1,267 participants over 24 weeks; Trial 02 enrolled 1,247 participants over the same duration. Both studies used identical endpoints and safety monitoring protocols, providing reproducible data across 2,514 total participants.

Nausea represented the most common treatment-emergent adverse event, occurring in 40% of bremelanotide recipients versus 13% receiving placebo. Critical nuance: nausea onset typically occurred within 30–60 minutes post-injection and resolved within 2–4 hours without intervention in 94% of cases. Only 3.7% of participants discontinued treatment due to nausea across both trials. Suggesting tolerability improves with repeated exposure, consistent with melanocortin receptor desensitization patterns observed in animal models.

Flushing occurred in 20% of treatment group participants, characterized as transient facial warmth and redness peaking at 45–90 minutes post-administration. Headache affected 11% of participants, with tension-type presentation rather than migraine characteristics. Injection site reactions. Erythema, mild pain, or bruising. Occurred in 8% of participants but led to discontinuation in fewer than 0.5% of cases.

Cardiovascular safety monitoring revealed transient blood pressure elevations in the immediate post-injection period. Mean systolic blood pressure increased 3–5 mmHg at the 90-minute mark, returning to baseline by hour four. Diastolic changes were minimal, averaging 1–2 mmHg. No participant experienced hypertensive crisis, and no statistically significant differences in cardiovascular events (myocardial infarction, stroke, arrhythmia) appeared between treatment and placebo groups over 24 weeks.

The safety profile extended cleanly across demographic subgroups. Age stratification (18–35 years, 36–45 years, 46+ years) showed no meaningful variation in adverse event rates. BMI categories from 18.5 to 35 kg/m² demonstrated comparable tolerability. Participants with controlled hypertension on stable antihypertensive therapy showed the same transient blood pressure pattern without exacerbated responses. Though uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg) remained an exclusion criterion.

Real Peptides supplies research-grade PT 141 Bremelanotide synthesized with exact amino acid sequencing and third-party purity verification. Critical factors that determine both efficacy and safety in controlled research settings. Peptide degradation products from improper storage or synthesis errors can introduce unpredictable receptor binding profiles that clinical trial data wouldn't capture.

Mechanism-Based Contraindications and Risk Factors

Understanding the PT-141 safety profile requires distinguishing between contraindications rooted in pharmacological mechanism versus those based on regulatory caution. Bremelanotide acts as a melanocortin receptor agonist with primary affinity for MC4R (melanocortin-4 receptor) and secondary affinity for MC1R and MC3R. MC4R activation in the hypothalamus modulates sexual arousal pathways but also influences cardiovascular tone through sympathetic nervous system activation. The mechanism underlying transient blood pressure elevation.

Uncontrolled hypertension represents the only absolute contraindication based on mechanism. Patients with baseline systolic blood pressure exceeding 160 mmHg or diastolic exceeding 100 mmHg were excluded from all clinical trials due to theoretical additive cardiovascular risk. The transient 3–5 mmHg increase observed in normotensive and controlled hypertensive participants becomes clinically meaningful when baseline pressures already approach critical thresholds.

Cardiovascular disease requiring active management warrants individual risk assessment rather than blanket contraindication. The RECONNECT trials excluded participants with recent (within 6 months) myocardial infarction, unstable angina, uncontrolled arrhythmias, or cerebrovascular accidents. Participants with stable coronary artery disease on medical therapy showed no increased adverse event rates. Suggesting stable cardiovascular status tolerates the transient sympathetic activation without consequence.

Renal impairment considerations stem from PT-141's clearance pathway. Bremelanotide undergoes minimal hepatic metabolism, with renal excretion representing the primary elimination route. Pharmacokinetic studies in participants with moderate renal impairment (eGFR 30–59 mL/min/1.73m²) showed 50% higher area-under-the-curve values compared to participants with normal renal function. Dose adjustment to 1.25mg from the standard 1.75mg maintained comparable plasma concentrations. Severe renal impairment (eGFR <30 mL/min/1.73m²) has not been adequately studied. Use in this population remains investigational.

Pregnancy and lactation represent regulatory contraindications without mechanism-based evidence of harm. Animal reproductive toxicology studies at doses 10–50 times human exposure showed no teratogenic effects, no impact on fertility, and no adverse developmental outcomes. However, no adequate well-controlled studies exist in pregnant humans, and melanocortin receptor expression in placental tissue creates theoretical (though undemonstrated) risk. The FDA assigned Pregnancy Category C. Risk cannot be ruled out.

Drug interaction potential is minimal due to non-hepatic metabolism. PT-141 does not inhibit or induce cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9, CYP2C19), meaning it won't alter plasma concentrations of medications metabolized through these pathways. Concurrent use of alpha-blockers, nitrates, or other blood pressure-lowering agents requires monitoring due to additive hypotensive effects during the 4-hour post-injection window. Though clinical trials allowed stable antihypertensive regimens without dose adjustment.

Skin hyperpigmentation from chronic MC1R activation represents a theoretical long-term risk based on melanotan II data (PT-141's parent compound). MC1R stimulation drives melanogenesis in dermal melanocytes, producing the tanning effect melanotan II became known for. PT-141 has lower MC1R affinity than melanotan II, and clinical trials up to 52 weeks showed no clinically significant hyperpigmentation in participants. Duration of exposure beyond one year remains understudied.

Peptide Purity and Contamination Risks in Research Settings

The PT-141 safety profile documented in pharmaceutical trials assumes >98% peptide purity and absence of synthesis byproducts. Standards that don't automatically apply to research-grade compounds sourced outside regulated pharmaceutical supply chains. Peptide synthesis through solid-phase methods generates deletion sequences, truncation products, and residual protecting groups that require high-performance liquid chromatography purification to remove. Inadequately purified peptides introduce molecules with unpredictable receptor binding profiles.

Deletion sequences. Peptides missing one or more amino acids from the intended sequence. Can retain partial agonist activity at melanocortin receptors while introducing off-target effects. A PT-141 analog missing the C-terminal arginine (position 7 in the heptapeptide structure) showed 60% reduced MC4R binding affinity in vitro but paradoxically increased MC3R activation. Shifting the receptor selectivity profile in ways that clinical safety data wouldn't predict.

Truncation products from incomplete synthesis or peptide bond hydrolysis create fragments that may act as partial agonists, antagonists, or allosteric modulators. Fragments containing the critical His-Phe-Arg-Trp pharmacophore retained measurable MC4R binding in receptor assays, though with altered signaling kinetics. The clinical implication: a vial labeled "PT-141 10mg" containing 8mg bremelanotide plus 2mg truncation products doesn't just represent reduced potency. It represents introduction of structurally related molecules with unknown safety profiles.

Bacterial endotoxin contamination from synthesis in non-sterile environments or inadequate purification represents a distinct safety concern. Endotoxins (lipopolysaccharides from gram-negative bacterial cell walls) trigger dose-dependent immune responses ranging from subclinical cytokine elevation to fever, hypotension, and disseminated intravascular coagulation at high exposures. The FDA sets endotoxin limits for injectable peptides at 5 endotoxin units per kilogram of body weight per hour. A threshold that assumes endotoxin testing occurred.

Residual solvents from synthesis. Trifluoroacetic acid, dimethylformamide, dichloromethane. Can persist in lyophilized peptide powder if vacuum drying was inadequate. TFA (trifluoroacetic acid) residues above 0.1% can cause injection site irritation and systemic acidosis with repeated administration. DMF (dimethylformamide) is hepatotoxic at cumulative doses, with documented cases of liver injury from contaminated pharmaceutical compounds. Research-grade peptides from suppliers without third-party solvent residue testing carry unknowable exposure levels.

Real Peptides conducts small-batch synthesis with post-production verification through mass spectrometry and HPLC, providing certificate-of-analysis documentation showing >98% purity and quantified impurity profiles. The distinction matters: a peptide showing 95% purity on HPLC contains 5% uncharacterized material. Potentially deletion sequences, truncation products, or synthesis byproducts. That clinical PT-141 safety profile data never evaluated. Our commitment to precision extends across our research peptide catalog, including compounds like BPC 157 Peptide and Thymosin Alpha 1 Peptide, where purity directly determines both research validity and safety margins.

PT-141 Safety Profile: Comparative Analysis

Understanding the PT-141 safety profile requires context. How do the adverse event rates, mechanism-based risks, and contraindication profiles compare to alternative interventions for sexual dysfunction? The table below positions PT-141 against PDE5 inhibitors (sildenafil) and testosterone replacement therapy based on published clinical trial data.

Safety Parameter	PT-141 (Bremelanotide 1.75mg SC)	Sildenafil (50–100mg Oral)	Testosterone Replacement (IM/Transdermal)	Professional Assessment
Primary Mechanism	MC4R agonist (central hypothalamic action)	PDE5 inhibitor (peripheral vascular action)	Androgen receptor agonist (systemic hormonal)	PT-141 uniquely targets CNS arousal pathways rather than vascular or hormonal mechanisms
Most Common Adverse Event	Nausea (40% vs 13% placebo)	Headache (16%), flushing (10%)	Acne (15%), polycythemia (5–10%), mood changes (8%)	Nausea with PT-141 is dose-dependent and transient; sildenafil side effects are vascular; TRT effects are systemic and persistent
Cardiovascular Risk	Transient BP elevation 3–5 mmHg (resolves in 4 hours)	Contraindicated with nitrates; hypotension risk in cardiac patients	Increased hematocrit (thrombotic risk), possible adverse lipid changes	PT-141 shows lowest cardiovascular risk in stable patients; TRT requires ongoing hematocrit monitoring
Hepatic Metabolism	None. Renal clearance only	Extensive CYP3A4 metabolism (drug interaction potential)	Hepatic metabolism with 17-alpha alkylated forms causing hepatotoxicity	PT-141 bypasses liver entirely, eliminating drug-drug interaction and hepatotoxicity concerns
Renal Considerations	Dose adjustment needed if eGFR 30–59 mL/min	Minimal. <2% renal excretion	Minimal direct renal effect	PT-141 uniquely requires renal function assessment before dosing
Contraindications	Uncontrolled hypertension (SBP >160 or DBP >100)	Nitrate use, recent MI, severe cardiac failure	Prostate cancer, male breast cancer, untreated severe sleep apnea, baseline hematocrit >50%	PT-141 has narrowest contraindication list; TRT has broadest due to systemic effects
Discontinuation Rate (Clinical Trials)	3.7% due to nausea	2–3% due to headache/flushing	5–8% due to polycythemia or mood effects	PT-141 discontinuation rates comparable to PDE5 inhibitors, lower than TRT

What If: PT-141 Safety Scenarios

What If My Blood Pressure Increases After Injection?

Measure your blood pressure at baseline before injection, then at 30, 60, and 90 minutes post-administration to document the peak effect. Clinical trial data shows mean systolic increases of 3–5 mmHg peaking at 90 minutes and resolving by hour four. Elevations above 10 mmHg systolic or persistence beyond four hours warrants medical evaluation. If baseline blood pressure is already elevated (systolic 140–159 or diastolic 90–99), the additive effect could push you into Stage 2 hypertension temporarily, increasing cardiovascular event risk during that window.

What If I Experience Persistent Nausea Beyond the First Few Hours?

Nausea from PT-141 typically peaks within 30–60 minutes and resolves within 2–4 hours due to transient melanocortin receptor activation in the area postrema (the brain's chemoreceptor trigger zone). Nausea persisting beyond six hours suggests either unusually high individual sensitivity to MC4R activation or, less commonly, peptide contamination with endotoxins that trigger broader immune responses. Try reducing the dose by 30% on the next administration. The RECONNECT trials demonstrated dose-dependent nausea rates, with lower doses (1.25mg vs 1.75mg) reducing incidence from 40% to approximately 25%.

What If I'm Taking Blood Pressure Medication — Is PT-141 Safe?

Participants in the RECONNECT trials on stable antihypertensive regimens (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics) showed no increased adverse event rates compared to normotensive participants, provided baseline blood pressure was controlled below 140/90 mmHg. The transient 3–5 mmHg systolic increase doesn't significantly alter the pharmacodynamics of most antihypertensive medications. Alpha-blockers represent the exception. Concurrent use creates theoretical additive hypotensive effects during the post-injection window, though no clinical trial data specifically examined this combination.

What If I Have Mild Kidney Impairment?

Mild renal impairment (eGFR 60–89 mL/min/1.73m²) requires no dose adjustment. Pharmacokinetic studies showed minimal changes in drug clearance within this range. Moderate impairment (eGFR 30–59 mL/min/1.73m²) increases area-under-the-curve by approximately 50%, necessitating dose reduction to 1.25mg from the standard 1.75mg to maintain comparable plasma exposure. Severe impairment (eGFR <30 mL/min/1.73m²) has not been adequately studied in clinical trials, and bremelanotide use in this population remains investigational with unknown safety margins.

The Evidence-Based Truth About PT-141 Safety

Here's the honest answer: the PT-141 safety profile from pharmaceutical-grade bremelanotide in controlled trials is exceptionally clean for a compound affecting centrally-mediated physiological processes. Far cleaner than most people assume given the mechanism of action. The nausea and flushing that occur in 40% and 20% of users respectively are predictable melanocortin receptor effects that resolve without intervention in over 90% of cases. The cardiovascular signal is minimal and transient, with mean blood pressure increases that fall within normal daily variation for most individuals.

What pharmaceutical trials don't capture: the safety profile of research-grade peptides depends entirely on synthesis quality and purity verification. A vial containing 92% PT-141 and 8% uncharacterized synthesis byproducts isn't delivering the same molecule that clinical trials evaluated. You're introducing deletion sequences, truncation products, and potential endotoxin contamination that create safety unknowns. The difference between >98% purity and 92% purity isn't a 6% reduction in potency. It's the introduction of structurally related compounds with unpredictable receptor binding profiles.

The regulatory distinction also matters. Bremelanotide received FDA approval for premenopausal women with hypoactive sexual desire disorder under the brand name Vyleesi. Meaning it underwent full Phase III evaluation with 2,514 participants over 24 weeks. Research-grade PT-141 supplied for investigational use hasn't undergone FDA review as a finished drug product, though the active molecule and its pharmacology remain identical. Safety in research settings requires the same attention to purity, storage, reconstitution sterility, and dosing precision that pharmaceutical manufacturing ensures through regulatory oversight.

The bottom line: PT-141's melanocortin receptor mechanism creates a fundamentally different safety calculation than vascular or hormonal interventions. The adverse events are transient and dose-dependent. The contraindication list is narrow. The drug interaction potential is minimal. But all of that assumes you're working with a peptide that matches the purity and characterization standards of what clinical trials actually tested.

Real Peptides exists because peptide research demands compounds that meet pharmaceutical-grade standards even when used in investigational contexts. Our full peptide collection reflects the same commitment to exact amino acid sequencing, third-party purity verification, and transparent certificate-of-analysis documentation that makes safety data from clinical trials applicable to real-world research applications.

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

PT-141 causes transient blood pressure elevation averaging 3–5 mmHg systolic at 90 minutes post-injection, returning to baseline within four hours in clinical trials. This effect stems from melanocortin-4 receptor activation in the hypothalamus, which modulates sympathetic nervous system tone. Participants with controlled hypertension on stable medication showed the same pattern without increased adverse events, provided baseline blood pressure remained below 140/90 mmHg. Uncontrolled hypertension exceeding 160/100 mmHg represents an absolute contraindication due to additive cardiovascular risk during the transient pressure increase.

PT-141 undergoes renal clearance without hepatic metabolism through cytochrome P450 enzymes, meaning it does not alter plasma concentrations of medications metabolized via CYP3A4, CYP2D6, or other hepatic pathways. Clinical trials allowed concurrent use of SSRIs, SNRIs, and most antihypertensive medications without dose adjustments or increased adverse events. The exception involves alpha-blockers, which may create additive hypotensive effects during the 4-hour post-injection window, though this combination was not specifically studied in controlled trials. Drug-drug interaction potential is minimal compared to most pharmaceutical interventions.

Pharmaceutical-grade bremelanotide under the brand name Vyleesi typically costs $800–$950 per dose through retail pharmacies, with insurance coverage varying based on diagnosis codes and prior authorization requirements. Research-grade PT-141 from verified suppliers ranges from $120–$280 per 10mg vial depending on purity certification and third-party testing documentation. The price difference reflects regulatory approval costs and branded manufacturing rather than molecular differences — the active peptide structure is identical. Research applications requiring precise dosing control and documented purity typically source from suppliers providing certificate-of-analysis verification like Real Peptides rather than pharmaceutical channels.

Nausea occurs in approximately 40% of PT-141 users versus 13% receiving placebo in Phase III trials, peaking within 30–60 minutes post-injection and resolving within 2–4 hours in 94% of cases. The mechanism involves melanocortin receptor activation in the area postrema, the brain region responsible for nausea and vomiting responses. Severity is dose-dependent — reducing from 1.75mg to 1.25mg decreases incidence to approximately 25% based on dose-ranging studies. Only 3.7% of trial participants discontinued due to nausea, suggesting most individuals develop tolerance with repeated exposure consistent with receptor desensitization patterns.

PT-141 has not been studied in pregnant or breastfeeding women through adequate well-controlled trials, and the FDA assigned Pregnancy Category C — risk cannot be ruled out. Animal reproductive toxicology studies at 10–50 times human exposure showed no teratogenic effects, fertility impairment, or adverse developmental outcomes. However, melanocortin receptors are expressed in placental tissue, creating theoretical risk pathways that remain uncharacterized in humans. Current medical guidance recommends discontinuing PT-141 before attempting conception and avoiding use during lactation until human safety data becomes available.

PT-141 demonstrates a distinctly different safety profile from PDE5 inhibitors like sildenafil (Viagra) or tadalafil (Cialis) due to central nervous system action rather than peripheral vascular effects. PT-141 shows no contraindication with nitrate medications, no risk of priapism, and minimal cardiovascular effects beyond transient 3–5 mmHg blood pressure elevation. PDE5 inhibitors cause headache and flushing through vascular dilation and carry absolute contraindications in patients using nitrates due to severe hypotension risk. PT-141’s primary adverse event — nausea in 40% of users — reflects melanocortin receptor activation rather than vascular mechanisms, making it mechanistically safer in patients with cardiovascular disease on stable medical therapy.

The longest controlled safety data for PT-141 comes from 52-week open-label extension studies following the 24-week Phase III trials, showing no new adverse events or safety signals with extended use. Theoretical long-term concerns include skin hyperpigmentation from chronic MC1R activation, similar to melanotan II effects, though PT-141’s lower MC1R affinity produced no clinically significant darkening in trials up to one year. Cardiovascular safety beyond 52 weeks remains understudied — the transient blood pressure response pattern continued unchanged with chronic dosing, suggesting no cumulative cardiovascular risk, but multi-year data does not exist in peer-reviewed literature.

Clinical trial protocols required baseline blood pressure measurement, electrocardiogram assessment, and basic metabolic panel including renal function (serum creatinine and eGFR calculation) before initiating PT-141. Ongoing monitoring involved blood pressure checks during the first several doses to characterize individual cardiovascular response patterns. Patients with moderate renal impairment (eGFR 30–59 mL/min/1.73m²) required dose adjustment to 1.25mg based on pharmacokinetic data showing 50% higher drug exposure. No hepatic function monitoring is necessary due to renal-only clearance, and no routine lab surveillance is required beyond initial assessment unless comorbid conditions warrant it.

Research-grade PT-141 safety requires peptide purity above 98% verified through high-performance liquid chromatography, with impurity characterization identifying deletion sequences, truncation products, and synthesis byproducts. Bacterial endotoxin testing must confirm levels below 5 endotoxin units per kilogram per hour to prevent immune activation and fever responses. Residual solvent analysis should verify trifluoroacetic acid below 0.1% and absence of hepatotoxic solvents like dimethylformamide. Peptides lacking third-party certificate-of-analysis documentation introduce uncharacterized molecules with unknown receptor binding profiles that clinical PT-141 safety data never evaluated — the difference between 98% purity and 92% purity is not potency but the presence of structurally related compounds with unpredictable safety margins.

Serious adverse events occurred in fewer than 2% of participants across Phase III trials enrolling 2,514 individuals, with no events determined to be causally related to bremelanotide by independent safety review boards. No deaths, cardiovascular events (myocardial infarction, stroke), or anaphylactic reactions were attributed to PT-141 in controlled studies. The most significant documented risk involves transient blood pressure elevation in individuals with uncontrolled baseline hypertension, which could theoretically precipitate hypertensive urgency if baseline systolic pressure exceeds 160 mmHg. Injection site infections from non-sterile reconstitution represent user-dependent risks rather than peptide-intrinsic toxicity — proper sterile technique with bacteriostatic water eliminates this concern.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA